Fintel reports that on April 25, 2025, Wells Fargo downgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

In a report released today, Tiago Fauth from Wells Fargo downgraded United Therapeutics (UTHR – Research Report) to a Hold, with a price target ...

Wells Fargo downgraded United Therapeutics (UTHR) to Equal Weight from Overweight with a price target of $314, down from $395.Stay Ahead of the ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00, and a low estimate of $314.00. This current average represents a 5.57% ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in United Therapeutics Corp (Symbol: UTHR), where a total of 2,163 contracts have traded ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its ...